The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | QoL benefits of jaktinib for myelofibrosis patients
Jie Jin
• 1 Jun 2021
Jie Jin, MD, PhD, Zhejiang Medical University, Hangzhou, China, discussess the benefits of jaktinib treatment for patients with myelofibrosis, higlighting improvements in quality of life (QoL). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
